Developing Nanoparticle-Based Therapeutics for Targeting the Microenvironment in Obesity-Induced Endometrial Cancer.

Area of Science:

• Oncology
• Biotechnology
• Nanomedicine

Background:

• Obesity is increasing endometrial cancer incidence, creating a public health concern.
• Adipose stem cells (ASCs) promote endometrial cancer growth by altering the tumor microenvironment via plasminogen activator inhibitor-1 (PAI-1).
• Limited therapeutic options exist for obesity-driven endometrial cancer.

Purpose of the Study:

• To develop a nanoparticle-based system for targeted delivery of PAI-1 siRNA.
• To inhibit the oncogenic microenvironment in obesity-driven endometrial tumors.

Main Methods:

• Developed in vitro and in vivo models to identify ASC integrin markers.
• Engineered lipid-coated mesoporous silica nanoparticles (LCMSNs) loaded with PAI-1 siRNA.
• Validated LCMSNs targeting and therapeutic efficiency in obese mice.

Main Results:

• Integrin alpha 7 (ITGA7) was identified as a specific marker on ASCs in the endometrial cancer microenvironment.
• Anti-ITGA7 antibody-conjugated LCMSNs effectively targeted ITGA7-positive ASCs.
• LCMSNs demonstrated strong uterine retention and PAI-1 gene silencing in vivo.

Conclusions:

• ITGA7-targeted LCMSNs represent a promising PAI-1 siRNA delivery system.
• This approach offers a potential therapeutic strategy against ASC-mediated oncogenesis in endometrial cancer.
• Further research will assess PAI-1 silencing efficacy in inhibiting tumor growth.